These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2899019)

  • 1. Effect of SMS 201-995 in rapidly progressive diabetic retinopathy.
    Lee HK; Suh KI; Koh CS; Min HK; Lee JH; Chung H
    Diabetes Care; 1988 May; 11(5):441-3. PubMed ID: 2899019
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
    Kirkegaard C; Nørgaard K; Snorgaard O; Bek T; Larsen M; Lund-Andersen H
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.
    Rios MS; Navascues I; Saban J; Ordoñez A; Sevilla F; Del Pozo E
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1071-4. PubMed ID: 2876005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
    Spinas GA; Bock A; Keller U
    Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration.
    Plewe G; Nölken G; Krause U; del Pozo E; Beyer J
    Scand J Gastroenterol Suppl; 1986; 119():166-9. PubMed ID: 2876502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a long-acting somatostatin derivative SMS 201-995 (sandostatin) on glucose homeostasis in type I diabetes mellitus.
    Navascues I; Gil J; Pascau C; Senén D; del Pozo E; Serrano-Ríos M
    Horm Res; 1988; 29(2-3):92-4. PubMed ID: 2900205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of somatostatin receptor ligands in obesity and diabetic complications.
    Boehm BO; Lustig RH
    Best Pract Res Clin Gastroenterol; 2002 Jun; 16(3):493-509. PubMed ID: 12079271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of diabetes after treatment with somatostatin analogue SMS 201-995 in an acromegalic patient.
    Cantalamessa L; Catania A; Baldini M; Orsatti A
    Horm Metab Res; 1986 Nov; 18(11):790-1. PubMed ID: 2878866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus.
    Plewe G; Noelken G; Krause U; Beyer J; del Pozo E
    Horm Res; 1987; 27(1):7-12. PubMed ID: 2887504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995.
    Mallet B; Vialettes B; Haroche S; Escoffier P; Gastaut P; Taubert JP; Vague P
    Diabete Metab; 1992; 18(6):438-44. PubMed ID: 1297600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study.
    McCombe M; Lightman S; Eckland DJ; Hamilton AM; Lightman SL
    Eye (Lond); 1991; 5 ( Pt 5)():569-75. PubMed ID: 1686591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological treatment of diabetic retinopathy].
    Lang GE
    Ophthalmologe; 2004 Dec; 101(12):1165-70. PubMed ID: 15592846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effect of the somatostatin analogue SMS-201995 on plasma glucose and triglycerides in insulin-dependent diabetic patients.
    Malerbi DA; de-Camargo JW; Cesar FP; Wajchenberg BL
    Braz J Med Biol Res; 1992; 25(6):593-600. PubMed ID: 1342235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMS 201-995 improves glucose tolerance in insulin-treated type II diabetic patients.
    Candrina R; Coppini A; Graffeo M; Zuccato F; Giustina G
    Diabetes Care; 1987; 10(4):534-5. PubMed ID: 2887407
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical treatment of diabetic retinopathy with somatostatin analogues.
    Palii SS; Caballero S; Shapiro G; Grant MB
    Expert Opin Investig Drugs; 2007 Jan; 16(1):73-82. PubMed ID: 17155855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy.
    Genovese S; Riccardi G
    J Endocrinol Invest; 2003; 26(8 Suppl):114-6. PubMed ID: 15233225
    [No Abstract]   [Full Text] [Related]  

  • 18. Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal.
    Diem P; Robertson RP
    Br J Clin Pharmacol; 1991 Nov; 32(5):563-7. PubMed ID: 1954071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study.
    Shumak SL; Grossman LD; Chew E; Kozousek V; George SR; Singer W; Harris AG; Zinman B
    Clin Invest Med; 1990 Oct; 13(5):287-92. PubMed ID: 2276223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
    Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.